August 21, 2014 11:43 AM ET


Company Overview of Neurotech Pharmaceuticals, Inc.

Company Overview

Neurotech Pharmaceuticals, Inc., a biotechnology company, develops sight-saving therapeutics for chronic retinal diseases in the United States. It offers NT-501, which is used for the treatment of geographic atrophy associated with atrophic age-related macular degeneration and retinitis pigmentosa; encapsulated cell technology platform, which allows sustained delivery of therapeutic factors to the back of the eye; and Neurotech Recovery-Back device that controls and treats back pain using transcutaneous electrical nerve stimulation and neuromuscular electrical stimulation. Neurotech Pharmaceuticals, Inc. was formerly known as Neurotech S.A and changed its name in May 2006. The company was fo...

701 George Washington Highway

Lincoln, RI 02865

United States

Founded in 1995





Key Executives for Neurotech Pharmaceuticals, Inc.

Chief Executive Officer
Age: 63
Executive Chairman
Age: 57
Chief Financial Officer and Vice President
Age: 59
Chief Medical Officer
Vice President of Core Technology Development
Compensation as of Fiscal Year 2014.

Neurotech Pharmaceuticals, Inc. Key Developments

Neurotech Pharmaceuticals, Inc. Announces New Appointments

Neurotech Pharmaceuticals, Inc. announced that renowned ophthalmology experts Eugene de Juan, Jr., M.D., and Lester Kaplan, Ph.D., have joined the company's board of directors. In addition, former Allergan Vice President and Therapeutic Area Head for ophthalmology, Rhett Schiffman, M.D., M.S., M.H.SA. has joined the company as its Chief Medical Officer. Along with the Neurotech team, Drs. de Juan and Kaplan will help advance the company's technology platform through the clinical development stage toward market availability. As CMO, Dr. Schiffman will lead the overall clinical development strategy as well as the design and execution of the various clinical programs at Neurotech. Eugene de Juan is a retinal surgeon, inventor and entrepreneur. He serves as Vice-Chairman of ForSight Labs. Lester Kaplan was Executive Vice President and President, Research & Development, and a board member of Allergan, Inc. Rhett Schiffman was most recently Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan.

Neurotech Pharmaceuticals, Inc. Appoints James Mazzo as Executive Chairman

Neurotech Pharmaceuticals, Inc. announced that James Mazzo was appointed the company's Executive Chairman. Mazzo, a long time leader in the ophthalmic industry, is the former CEO of Abbott Medical Optics (AMO). As Executive Chairman, Mazzo will engage with the Neurotech team to advance the company's novel technology platform through the clinical development stage toward market availability. Jim Mazzo's 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO). He was previously with Allergan for over 20 years in a variety of expanding roles, working and living in the U.S., England, Italy and Canada.

Similar Private Companies By Industry

Company Name Region
Arrowhead Madison, Inc. United States
Shamrock Structures LLC United States
Janus Biotherapeutics, Inc. United States
UroSurge, Inc. United States
Femina Pharma Incorporated United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neurotech Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at